Member Info for Mafuta

The activities of the MM will have to end soon ... They will have a time limit to finish their shenanigans ... All they will do at best is gather a few handfuls from the bed wetters and boy racers ... Their next trick will be to allow the price to rise ... That will gain them a few more handfuls ... The truth is that the real LTH will not let go as they know what the potential is ... They are in until the fat lady sings ... Tra-la-la-la

Any canny LTH would not set a stop loss ... That's the preserve of the bed wetters and boy racers ... Love, hugs and kisses Mafuta

Not the share price ... that's for sure ... and consequently not the MCap either ... What they are thinking about is getting the most value for the IP they have ... That's their bargaining chip and the HNWI know this too ... You can moan as much as you like about the share price whilst our BOD do what they do best ,.. develop our IP to the point where they can get the best offer ... It is after all our company's raison d'etre ... Love, hugs and kisses etc. Mafuta

From Edison:
Sareum’s H122 results (to end-December 2021) provided an update on the company’s progress with its therapeutic pipeline. With final toxicology and safety studies for lead asset SDC-1801 completed in Q4 of CY21 (final report expected by end-Q122), the company is on track to file an exploratory clinical trial application (CTA) in mid-2022 and start clinical studies in H222. The cash balance of £5.6m at the end of H1 should be sufficient to take SDC-1801 through Phase Ia clinical trials and accelerate SDC-1802’s preclinical progress, with the company continuing to assess options to further clinical development. Sareum completed the 50:1 share consolidation it announced at the December 2021 AGM, with the new shares starting trading on 1 March.

SDC-1801 remains on track to enter the clinic in 2022

SDC-1801, Sareum’s lead TYK2/JAK1 inhibitor, is on track for a mid-2022 CTA filing and a subsequent clinical entry in H2 CY22 after completion of final pre-clinical toxicology studies in Q421. While the full study will be available towards the end of March, early findings are encouraging and Sareum says they support its clinical plans. Development of the capsule formulation is progressing on schedule, with the synthesis of the drug’s active pharmaceutical ingredient (API) under Good Manufacturing Practice (GMP) conditions nearing completion.

SDC-1801 trial design

As per available information, the Phase Ia study would be a safety and dose-finding (ascending doses) study in healthy volunteers, with the initial target indication to be decided thereafter. The trial will also investigate early efficacy signals by looking at SDC-1801’s effect on certain biomarkers of autoimmune disease. The company indicated it is working with specialist clinical trial consultants to design the trial and we expect more details in the coming months. According to management, cash at end-December 2021 (£5.6m) remains sufficient to complete the Phase Ia study, after which the company will assess further fundraising or outlicensing/partnerships to progress SDC-1801’s clinical development.

Share consolidation complete

After the company’s communication of a planned share consolidation in 2022, Sareum effected a 50:1 share consolidation from 1 March. The key objective was to help improve Sareum’s attractiveness to institutional investors.

https://twitter.com/Edison_Inv_Res/status/1501618566314999813?t=rllf20LLXC--XgwzAhM7sQ&s=19

Been here done that ... and all LTH's have the tee shirts and scars to prove it ... Said it before if you are going to set stop losses on AIM then you deserve what you get ... sorry ... The MMs always win on thin volume ... Some LTH's with funds have scored today ... Sadly it's the wrong side of the tax year otherwise I would have been one of them ... Whinge and moan as much as you like about our BOD ... The science is intact and soon we will have news and they will be the best thing since sliced bread ... "A fickle heart is the only constant in this world" ... Love hugs and kisses Mafuta

Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that it has signed an exclusive distribution agreement with Geistlich Biomaterials Italia ("Geistlich"), a subsidiary company of Geistlich Pharma AG, a global company with a focus on regenerative products for bone, cartilage and tissue, for the distribution of OrthoPure XT in Italy.

Tells me the MMs are still filling orders ... Not much to say until the tox report lands ... Just filter out the noise ... Love, hugs and kisses Mafuta

More positive news ... What's not to like?

April 19th

POLB 001, a treatment for severe Influenza, remains on track to commence its bacterial lipopolysaccharide (LPS) human challenge trial in June 2022. Human data is expected before year end, at which point the Company aims to monetise by partnering or out licensing the product to pharma / biotech

- Continued expansion and diversification of the portfolio, reducing risk due to having multiple shots on goal;

o POLB 002 - in-licensed first-in-class, intranasally administered, RNA-based immunotherapy for respiratory virus infections

o Option to licence and evaluate an intramuscular vaccine to prevent Melioidosis (POLB 003), a disease predominately found in tropical and sub-tropical regions, and five additional bacterial vaccine candidates

o Oral Vaccine Delivery Platform - licensed access to use micro- and nanoencapsulation technology to develop oral vaccines for multiple disease indications

- In February 2022 the Company signed its first Artificial Intelligence (AI) deal with OneThree Biotech Inc. to identify new treatments for Respiratory Syncytial Virus ('RSV') through analysis of Poolbeg's unique human challenge trial data and OneThree's clinically validated biology driven platform

- Well capitalised with a strong cash balance of £20.9m at period end, following the IPO fundraise of £23.2m (after expenses)
- Loss for the period amounted to £2.3m including the initial non-recurring costs of establishing the Group
- The Company has significant financial resources and will maintain its capital light approach to support its pipeline expansion and development
- Scientific Advisory Board strengthened with the appointment of Professor Daniel Hoft joining Professor Luke O'Neill and Dr Elaine Sullivan

More in the RNS ... Looking good

That's the European listing. Google is likely recalibrating for the consolidation ... Don't panic Mr Mainwaring

https://twitter.com/sparksinsurrey/status/1498324069535649794?t=3UjnbJukYvvhU9_lwgcXPw&s=19

RMM I have always respected you as a poster and would like to say thank you for the comprehensive overview of the meeting .. lots to pore over and a confirmation of what's to come ... Well done for all your effort ... Mafuta

It's in the RNS but for those who cannot find it: 2:30 p.m. on 28 February 2022 at The City Centre, 80 Basinghall Street, London EC2V 5AG

This is the relevant paragraph:
"Application will be made for the New Ordinary Shares to be admitted to trading on AIM in place of the Existing Ordinary Shares. Subject to the Consolidation Resolution being passed, dealings in the Existing Ordinary Shares will cease at the close of business on the date of the Extraordinary General Meeting. It is expected that Admission will become effective and that dealings in the New Ordinary Shares will commence on 1 March 2022."
Regards Mafuta

What we are seeing at this stage can be best seen as the "flaying hooves of a dead horse" this is a last ditch attempt to squeeze the shares out of nervous investors ... They know their chances fade post consolidation ... Love hugs and kisses Mafuta

Yep ... Serious monkey business going on ... And despite the irony that's good news ... Keep your hand on your happeny ... Don't think it's too long now ... Xxx

Sorry to hear that film ... A good reminder that despite the whole country relaxing and letting their guard down Covid is still a killer ... Best regards Mafuta